• Title/Summary/Keyword: Therapeutic rate

Search Result 1,097, Processing Time 0.028 seconds

Intracoronary Radiation Therapy Using Re-188 after percutaneous Coronary Angioplasty (경피적 관동맥혈관성형술 후 Re-188을 이용한 혈관 내 방사선조사요법)

  • Chae, In-Ho;Lee, Myoung-Mook;Lee, Dong-Soo
    • 대한핵의학회:학술대회논문집
    • /
    • 1999.05a
    • /
    • pp.228-241
    • /
    • 1999
  • Percutaneous coronary angioplasty is well established therapeutic modality in the management of coronary artery disease. However, the high restenosis rate of 30 to 50% limits its usefulness. The principal mechanism of restenosis, intimal hyperplasia, is the proliferative response of vessel wall to injury, which consists largely of smooth muscle cells. A large body of animal investigations and a limited number of clinical studies have established the ability of ionizing radiation to reduce neointimal proliferation and restenosis rate significantly. Human studies have been reported that intravascular radiation after first restenosis inhibits a second restenosis. Encouraged by these reports, we are also conducting a double blind, placebo-controlled, randomized trial to evaluate this new therapeutic modality in patients with coronary artery stenosis. The objective of our trial is to determine the safety and efficacy of catheter-based solutional beta emitting radioisotope system in preventing restenosis after angioplasty. This review describes the vascular brachytherapy systems and isotopes that have been utilized in the initial clinical trials performed in this area of post PTCA coronary restenosis. The results of many worldwide ongoing clinical trials will determine whether this new technology will change the future practice of vascular intervention.

  • PDF

Postoperative Radiation Therapy of Astrocytoma and Glioblastoma Multiforme (성상세포종과 교아세포종의 수술후 방사선치료)

  • Park, Moon-Baik;Hong, Seong-Eon
    • Radiation Oncology Journal
    • /
    • v.7 no.1
    • /
    • pp.23-27
    • /
    • 1989
  • Forty-four patients with brain astrocytoma and glioblastoma were rested with surgical resection and postoperative radiation from January 1980 through May 1987, Four patients were lost to follow up, and in 40 patients survival time was evaluable. Three year actuarial survival rate was $66.7\%$ in Grade I and II astrocytoma, $30\%$ in Grade III, and $20.4\%$ in glioblastoma multiforme patients. The prognostic factors affecting survival rate were histologic grade in all cases, age, and total radiation dose in Grade III and glioblastoma.

  • PDF

New Methods of Vagus Nerve Stimulation : Therapeutic Effects of Non-Invasive Vagus Nerve Stimulation by TENS Application (미주신경 자극을 위한 새로운 방법 : 비침습적 TENS 적용에 대한 미주신경 자극의 치료적 효과)

  • Kwon, Haeyeon;Moon, Hyunju
    • Journal of The Korean Society of Integrative Medicine
    • /
    • v.4 no.4
    • /
    • pp.77-82
    • /
    • 2016
  • Purpose: The purpose of this study was to investigate the therapeutic effect of non-invasive vagus nerve stimulation by transcutaneous electrical nerve stimulation application on the autonomic nervous system of human body. Methods: Participants were seventeen healthy adults. Standard deviation of all normal N-N intervals(SDNN), root mean square of successive differences(RMSSD), low frequency(LF), high frequency(HF) were compared in pre and post Mean values after intervention. Data were analyzed in Wilcoxon's signed-ranks test. Results: The results of this study is that sistolic blood pressure and pulse rate decreased mean value after non-invasive vagus nerve stimulation by transcutaneous electrical nerve stimulation. High frequency, low frequency, SDNN, RMSSD increased mean value in heart rate variability after intervention. But that is not significant except for SDNN. Conclusion: Non-invasive vagus stimulation by transcutaneous electrical nerve stimulation effect on parasympathetic nerve stimulation, and then it might be effective method for autonomic nerve balance control.

Accuracy of Dose Estimation in High Dose Rate Intracavitary Radiotherapy of Carcinoma of the Uterine Cervix (자궁경부암 고선량율 강내치료의 치료선량 정확도에 관한 연구)

  • Huh, Seung-Jae;Ha, Sung-Whan;Chai, Kyu-Young
    • Radiation Oncology Journal
    • /
    • v.5 no.2
    • /
    • pp.137-140
    • /
    • 1987
  • In brachytherapy of uterine conical cancer using a high dose rate remote afterloading system, it is of prime importance to deliver a accurate dose in each fractionated treatment by minimizing the difference between the pre-treatment planned and post-treatment calculated doses. The post-treatment calculated point A dose was not much different from the pretreatment planned dose (500 cGy). The $average{\pm}standard$ deviation was $500\pm18cGy$ and 84 percent of 82 intracavitary radiotherapy was within the range of $500\pm25cGy$.

  • PDF

Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management

  • Pieralice, Silvia;Pozzilli, Paolo
    • Diabetes and Metabolism Journal
    • /
    • v.42 no.6
    • /
    • pp.451-464
    • /
    • 2018
  • Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease characterized by a less intensive autoimmune process and a broad clinical phenotype compared to classical type 1 diabetes mellitus (T1DM), sharing features with both type 2 diabetes mellitus (T2DM) and T1DM. Since patients affected by LADA are initially insulin independent and recognizable only by testing for islet-cell autoantibodies, it could be difficult to identify LADA in clinical setting and a high misdiagnosis rate still remains among patients with T2DM. Ideally, islet-cell autoantibodies screening should be performed in subjects with newly diagnosed T2DM, ensuring a closer monitoring of those resulted positive and avoiding treatment of hyperglycaemia which might increase the rate of ${\beta}-cells$ loss. Thus, since the autoimmune process in LADA seems to be slower than in classical T1DM, there is a wider window for new therapeutic interventions that may slow down ${\beta}-cell$ failure. This review summarizes the current understanding of LADA, by evaluating data from most recent studies, the actual gaps in diagnosis and management. Finally, we critically highlight and discuss novel findings and future perspectives on the therapeutic approach in LADA.

Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-κB Activity in Triple-Negative Breast Cancer Cells

  • Ma, Chaobing;Zu, Xueyin;Liu, Kangdong;Bode, Ann M.;Dong, Zigang;Liu, Zhenzhen;Kim, Dong Joon
    • Molecules and Cells
    • /
    • v.42 no.9
    • /
    • pp.628-636
    • /
    • 2019
  • Altered genetic features in cancer cells lead to a high rate of aerobic glycolysis and metabolic reprogramming that is essential for increased cancer cell viability and rapid proliferation. Pyruvate kinase muscle (PKM) is a rate-limiting enzyme in the final step of glycolysis. Herein, we report that PKM is a potential therapeutic target in triple-negative breast cancer (TNBC) cells. We found that PKM1 or PKM2 is highly expressed in TNBC tissues or cells. Knockdown of PKM significantly suppressed cell proliferation and migration, and strongly reduced S phase and induced G2 phase cell cycle arrest by reducing phosphorylation of the CDC2 protein in TNBC cells. Additionally, knockdown of PKM significantly suppressed $NF-{\kappa}B$ (nuclear factor kappa-light-chain-enhancer of activated B cells) activity by reducing the phosphorylation of p65 at serine 536, and also decreased the expression of $NF-{\kappa}B$ target genes. Taken together, PKM is a potential target that may have therapeutic implications for TNBC cells.

Epigenetic Silencing of CHOP Expression by the Histone Methyltransferase EHMT1 Regulates Apoptosis in Colorectal Cancer Cells

  • Kim, Kwangho;Ryu, Tae Young;Lee, Jinkwon;Son, Mi-Young;Kim, Dae-Soo;Kim, Sang Kyum;Cho, Hyun-Soo
    • Molecules and Cells
    • /
    • v.45 no.9
    • /
    • pp.622-630
    • /
    • 2022
  • Colorectal cancer (CRC) has a high mortality rate among cancers worldwide. To reduce this mortality rate, chemotherapy (5-fluorouracil, oxaliplatin, and irinotecan) or targeted therapy (bevacizumab, cetuximab, and panitumumab) has been used to treat CRC. However, due to various side effects and poor responses to CRC treatment, novel therapeutic targets for drug development are needed. In this study, we identified the overexpression of EHMT1 in CRC using RNA sequencing (RNA-seq) data derived from TCGA, and we observed that knocking down EHMT1 expression suppressed cell growth by inducing cell apoptosis in CRC cell lines. In Gene Ontology (GO) term analysis using RNA-seq data, apoptosis-related terms were enriched after EHMT1 knockdown. Moreover, we identified the CHOP gene as a direct target of EHMT1 using a ChIP (chromatin immunoprecipitation) assay with an anti-histone 3 lysine 9 dimethylation (H3K9me2) antibody. Finally, after cotransfection with siEHMT1 and siCHOP, we again confirmed that CHOP-mediated cell apoptosis was induced by EHMT1 knockdown. Our findings reveal that EHMT1 plays a key role in regulating CRC cell apoptosis, suggesting that EHMT1 may be a therapeutic target for the development of cancer inhibitors.

Radiation Therapy of Primary Carcinoma of the Vagina (원발성 질암의 방사선치료)

  • Huh, Seung-Jae;Shin, Kyung-Hwan;Ahn, Yong-Chan;Ha, Sung-Whan;Park, Charn-Il
    • Radiation Oncology Journal
    • /
    • v.13 no.1
    • /
    • pp.63-67
    • /
    • 1995
  • A retrospective study was carried out of 20 patients with histologically proven invasive carcinoma of the vagina from 1979 to 1993; 17 cases with curative primary radiotherapy and three cases with postoperative radiotherapy. The five and ten year overall survival rates were $79\%$ and $53\%$, respectively. Survival was strongly correlated with stage. Five year survival rates of stage I, stage II, and stage III, IV were $100\%$, $78\%$, and $0\%$, respectively. Eight patients experienced recurrences: five within the irradiated volume, two distant metastasis, and one combined both local and distant metastasis. There was no significant late complication. From these data, radiation is effective in the management of the vaginal cancer patients and optimum treatment modality and total dose recommendation are made.

  • PDF

Radiotherapy Results of Malignant Astrocytoma and Glioblastoma Multiforme (악성 성상세포종과 교아세포종의 방사선 치료성적)

  • Choi, Doo-Ho;Lee, Hae-Kyung;Hong, Seong-Eon
    • Radiation Oncology Journal
    • /
    • v.10 no.2
    • /
    • pp.163-169
    • /
    • 1992
  • A retrospective analysis was performed on 53 patients with brain malignant astrocytoma and glioblastoma multiforme treated with surgical resection and postoperative radiotherapy in the period between January 1980 and June 1991. There were 13 patients with malignant astrocytoma, 40 patients with glioblastoma multiforme. Survival rates were analyzed according to histologic grade, age, performance status, extent of surgical resection, tumor location, symptom duration, total radiation dose and addition of chemo­therapy after radiation therapy. 5 year actuarial survival rate for malignant astrocytoma was $29.4\%$, for glioblastoma multiforme was $2.8\%$. Histologic grade, age, performance status, total radiation dose were statistitically significant prognostic factors.

  • PDF

The Effect of human Immunoglobulin and Chorionic Gonadotropin on the Production of Maternal Blocking Antibody (인혈청(人血淸) 면역글로부린 및 융모성성선자극호르몬이 습관성유산환자의 혈청내 '차단항체' 생성에 미치는 영향)

  • Park, Moon-Il
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.20 no.2
    • /
    • pp.149-156
    • /
    • 1993
  • Human chorionic gonadotropin(hCG) and intravenous immunoglobulin(IVIG) treatment were attempted as a novel therapeutic approach for unexplained recurrent spontaneous abortion(RSA). Forty-four and 3 women with a history of RSA were treated with hCG and IVIG, respectively, during pregnancy. Of these patients, serum blocking factor assay was performed before and after each treatment, in 15 patients; 12 cases with hCG and 3 cases with IVIG. The results were as follows: 1. Of 44 women who receive hCG during pregnancy, 24 delivered healthy infants at term, 10 patients suffered repeat abortion, and 10 women are still pregnant under 28 weeks. Over all success rate of hCG treatment was 70.6% (24/34). Although there is no statistical significance, absolute serm blocking level was decreased after treatment(N=12). 2. Of 3 women who receive IVIG during pregnancy, all 3 women are still pregnant under 28 weeks. Serum blocking level was increased after treatment, however, this increment was not statistically significant. Although no conclusion could be extracted from the patients who received IVIG, the therapeutic effect of hCG is comparable to that of the other therapeutic regimens, such as allogeneic leukocytes. It was postulated that actual etiology of unknown RSA would be classified as hormonal origin although combined etiologies are common in Korean women.

  • PDF